In Silico Identification and Mechanistic Characterization of Cyanobacterial Metabolites as Potential CD38 Inhibitors for Multiple Myeloma
Authors:
- 12 October 2026
- journal article
- research article
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 22 (1) , 253
Abstract
No abstract availableKeywords
Funding Information
- “Tianshan Talents” Medical and Health High-level Talent Training Program (TSYC202401A064)
This publication has 32 references indexed in Scilit:
- Computational Insights into Aldose Reductase Inhibition by Soy Isoflavones: A Pathway To Diabetes MitigationJournal of Pharmaceutical Innovation, 2025
- Exploring marine-derived compounds as potential anticancer agents: Mechanisms and therapeutic implicationsCancer Pathogenesis and Therapy, 2025
- Exploring the anti-cancer potential of daidzin in breast cancer: Integrated bioinformatics and computational insights on oncogene inhibitionComputational Biology and Chemistry, 2025
- Marine-derived secondary metabolites in oncology: A comprehensive reviewCurrent Research in Biotechnology, 2025
- Approaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?Indian Journal of Hematology and Blood Transfusion, 2025
- Marine natural products as a source of novel anticancer drugs: an updated review (2019–2023)Natural Products and Bioprospecting, 2025
- A Covalent Binding Mode of a Pyrazole‐Based CD38 InhibitorHelvetica Chimica Acta, 2023
- Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomesAnnals of Hematology, 2022
- A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ DeclineCell Metabolism, 2018
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996